Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Barbara J. Brennan"'
Autor:
Marwan Fakih, Kanwal Pratap Singh Raghav, David Z. Chang, Tim Larson, Allen L. Cohn, Timothy K. Huyck, David Cosgrove, Joseph A. Fiorillo, Rachel Tam, David D'Adamo, Neelesh Sharma, Barbara J. Brennan, Ying A. Wang, Sabine Coppieters, Hong Zebger-Gong, Anke Weispfenning, Henrik Seidel, Bart A. Ploeger, Udo Mueller, Carolina Soares Viana de Oliveira, Andrew Scott Paulson
Publikováno v:
EClinicalMedicine, Vol 58, Iss , Pp 101917- (2023)
Summary: Background: Anti-programmed cell death protein 1 antibodies plus multikinase inhibitors have shown encouraging activity in several tumour types, including colorectal cancer. This study assessed regorafenib plus nivolumab in patients with mic
Externí odkaz:
https://doaj.org/article/607bb200b67a4b90be60f4ef3e49d300
Autor:
Katharina Lechner, Izolda Franjkovic, Emily Labriola-Tompkins, Martin Hutchings, Jurriaan Brouwer-Visser, Mark DeMario, Alex F. Herrera, Javier Briones, Eirini Bournazou, Eveline Nüesch, Michael Dickinson, Dominik Rüttinger, Nilanjan Ghosh, Sarah C. Rutherford, Barbara J. Brennan, Martin Kornacker, Evelyne Chesne, Raul Cordoba, Eva González-Barca
Publikováno v:
Blood Advances
Key Points BET inhibitor RO6870810+venetoclax+rituximab has a manageable safety profile in relapsed/refractory diffuse large B-cell lymphoma.A clinically relevant signal of antitumor activity serves as a proof of principle for this combination, warra
Autor:
Daniel Tan, Koichi Goto, Herbert HF Loong, Tsung-Ying Yang, Shirish Gadgeel, Erminia Massarelli, Gennaro Daniele, Xiuning Le, Yuki Shinno, Haruyasu Murakami, Tomohiro Sakamoto, Jose C. Ruffinelli, Shun Lu, Yiping Zhang, Tae Min Kim, Barbara J. Brennan, Chunlin Chen, Miranda Joosten, Zebin Wang, Su-Fen Pu, Weichao Bao, Martin Kornacker, Roberta Ferraldeschi, Paolo Grassi, Boon Cher Goh
Publikováno v:
Cancer Research. 83:CT126-CT126
Background: Despite targeted agents recently approved for treating patients with advanced NSCLC harboring EGFR exon 20 insertion (ex20ins) mutations, there is still a high unmet need for more effective agents with good tolerability. BAY2927088 is an
Autor:
Pinkal Desai, Barbara J. Brennan, Eveline Nüesch, Sangmin Lee, Eric S. Winer, Laura Brennan, Martin Kornacker, Daniel J. DeAngelo, Evelyne Chesne, Gail J. Roboz, Mark DeMario, Ellen K. Ritchie, Katharina Lechner
Publikováno v:
Leukemialymphoma. 62(7)
Bromodomain and extra-terminal (BET) proteins can drive carcinogenesis and therapy resistance. RO6870810 (RO) is a novel, small-molecule BET inhibitor. We conducted a study in 32 patients with relapsed/refractory acute myeloid leukemia and hypomethyl
Autor:
Debra L. Richardson, Geoffrey I. Shapiro, Iben Spangaard, Martin Kornacker, Mark DeMario, Izolda Franjkovic, Emily Labriola-Tompkins, Erika Hamilton, Evelyne Chesne, Barbara J. Brennan, Katharina Lechner, Stephanie Lheureux, George Au-Yeung, Eveline Nueesch
Publikováno v:
Cancer Research. 81:LB104-LB104
Background: Transcriptional activation of c-MYC through bromodomain and extra-terminal (BET) proteins contributes to the malignant phenotype of OC and TNBC. RO is a novel thienodiazepine, small molecule, non-covalent inhibitor of the BET family of br
Autor:
William P. Harris, Max W. Sung, Dirk Waldschmidt, Ying A. Wang, Tatiane Cristine Ishida, Richard D. Kim, Udo Mueller, Barbara J. Brennan, Vittorio Luigi Garosi, Hong Zebger-Gong, Peter R. Galle, Anthony B. El-Khoueiry, Roniel Cabrera
Publikováno v:
Journal of Clinical Oncology. 39:4078-4078
4078 Background: REG, a multikinase inhibitor, and PEMBRO, an anti-PD-1 mAb, are approved as monotherapies in advanced HCC after progression on sorafenib. This phase 1b dose-finding study investigated first-line REG plus PEMBRO in advanced HCC. Metho
Autor:
Jinzi J Wu, Hui Li, Jia-Horng Kao, Isabel Najera, James Thommes, Barbara J. Brennan, Youn-Jae Lee, Satawat Thongsawat, Shui-Yi Tung, George Hill, I-Shyan Sheen, Tawesak Tanwandee, Julian Zhou, Sophie Le Pogam
Publikováno v:
Journal of Gastroenterology and Hepatology. 31:1757-1765
Background and Aim Chronic hepatitis C is an important public health problem in Asia. We evaluated the safety, efficacy, and pharmacokinetics of fixed-dose ritonavir-boosted danoprevir plus peginterferon alfa-2a/ribavirin in treatment-naive Asian pat
Autor:
Peter N. Morcos, Athina Voulgari, Edward Gane, Regine Rouzier, James Thommes, Catherine A.M. Stedman, Barbara J. Brennan, Astrid Scalori, Włodzimierz Mazur, Tarek Hassanein, Simon Eng, Sophie Le Pogam, V. Kupčová
Publikováno v:
Hepatology International. 10:478-487
Effective and safe antiviral treatment regimens are needed for patients with chronic hepatitis C (CHC) and cirrhosis. An international open-label trial was conducted in CHC patients with genotype (G)1/4 infection, compensated cirrhosis, HCV RNA ≥ 5
Autor:
Annabelle Lemenuel-Diot, Navita L. Mallalieu, Jonathan Solsky, Eric Snoeck, Cynthia Wat, Michael J. McKenna, Barbara J. Brennan
Publikováno v:
British Journal of Clinical Pharmacology. 81:658-666
AIM The aim of the study was to simplify the dosing regimen of peginterferon alfa-2a in paediatric patients with chronic hepatitis C. METHODS A population pharmacokinetic (PK) model was developed using PK data from 14 children aged 2-8 years and 402
Autor:
M. De Mario, Eveline Nueesch, Raul Cordoba, R. Advani, T. Friess, Emily Labriola-Tompkins, Barbara J. Brennan, Nilanjan Ghosh, Martin Hutchings, Katharina Lechner, Michael Dickinson, Alex F. Herrera, J. Briones Mejjide, Jurriaan Brouwer-Visser, Evelyne Chesne, Sarah C. Rutherford, E. González Barca, Eirini Bournazou
Publikováno v:
Hematological Oncology. 37:174-175